Loading...
Combining milatuzumab (anti-CD74 humanized antibody) with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines
PURPOSE: The humanized anti-CD74 monoclonal antibody, milatuzumab, is in clinical evaluation for the therapy of multiple myeloma (MM). The ability of milatuzumab to increase the efficacy of bortezomib, doxorubicin, and dexamethasone was examined in three human CD74+ MM cell lines, CAG, KMS11, KMS12-...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2009
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2681251/ https://ncbi.nlm.nih.gov/pubmed/19351768 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-1953 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|